Hospira Inc (HSP.N)

HSP.N on New York Stock Exchange

53.85USD
19 Sep 2014
Price Change (% chg)

$0.34 (+0.64%)
Prev Close
$53.51
Open
$53.92
Day's High
$54.09
Day's Low
$53.61
Volume
487,456
Avg. Vol
210,463
52-wk High
$56.77
52-wk Low
$38.12

HSP.N

Chart for HSP.N

About

Hospira, Inc. (Hospira) is a provider of injectable drugs and infusion technologies. Hospira's portfolio includes generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management products. Hospira conducts operations worldwide and is managed in three reportable segments: Americas;... (more)

Overall

Beta: 0.53
Market Cap (Mil.): $9,086.21
Shares Outstanding (Mil.): 168.73
Dividend: --
Yield (%): --

Financials

  HSP.N Industry Sector
P/E (TTM): 52.10 32.70 33.56
EPS (TTM): 1.03 -- --
ROI: 3.19 18.13 17.36
ROE: 5.67 18.84 18.23
Search Stocks

Exclusive: Hospira talks with Danone on $5 billion tax inversion deal stall

LONDON - U.S. drugmaker Hospira’s HSP.N talks to buy the medical nutrition unit of Danone DANO.PA and use the deal to move its tax domicile abroad have stalled, according to people familiar with the matter, as attempts by U.S. companies to relocate abroad and cut their tax bills draw growing criticism back home.

03 Sep 2014

U.S. judge blocks FDA rule allowing generic versions of Hospira drug

- A federal judge has issued a temporary restraining order against the U.S. Food and Drug Administration's decision to allow the sale of generic versions of the Hospira Inc sedative Precedex.

20 Aug 2014

U.S. judge blocks FDA rule allowing generic versions of Hospira drug

- A federal judge has issued a temporary restraining order against the U.S. Food and Drug Administration's decision to allow the sale of generic versions of the Hospira Inc sedative Precedex.

20 Aug 2014

U.S. judge blocks FDA rule allowing generic versions of Hospira drug

Aug 20 - A federal judge has issued a temporary restraining order against the U.S. Food and Drug Administration's decision to allow the sale of generic versions of the Hospira Inc sedative Precedex.

20 Aug 2014

Hospira sues U.S. FDA over approval of generic sedative

- Drugmaker Hospira Inc has sued the Food and Drug Administration over its decision to open the doors for competitors to sell generic versions of its patented sedative, Precedex.

19 Aug 2014

Top U.S. lawmaker urges Hospira not to flee tax system

WASHINGTON - A senior U.S. senator said on Thursday he has written to Hospira Inc and urged the drug and medical device maker not to move its tax domicile abroad to save on U.S. taxes.

14 Aug 2014

UPDATE 1-Top U.S. lawmaker urges Hospira not to flee tax system

(Adds details of Durbin letter, Wyden comment, background, byline)

14 Aug 2014

Senior U.S. lawmaker urges Hospira not to flee U.S. tax system

WASHINGTON, Aug 14 - A senior U.S. senator said on Thursday he has written to the chief executive of Hospira Inc and urged the drug and medical device maker not to move its tax domicile abroad to save on U.S. taxes.

14 Aug 2014

Hospira beats profit estimates, raises 2014 outlook

- Hospira Inc , a pharmaceutical and medical device maker, posted a better-than-expected quarterly profit on higher sales of specialty injectable drugs, and raised its full-year outlook.

30 Jul 2014

Hospira beats profit estimates, raises 2014 outlook

July 30 - Hospira Inc, a pharmaceutical and medical device maker, posted a better-than-expected quarterly profit on higher sales of specialty injectable drugs, and raised its full-year outlook.

30 Jul 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Jefferson Research
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks